" class="no-js "lang="en-US"> AstraZeneca Archives - Medtech Alert
Friday, March 01, 2024

Sort by:

Date

Top Post

Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease

An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]

Quell Therapeutics Signs Agreement with AstraZeneca to Develop and Commercialize Engineered Treg Cell Therapies for Autoimmune Diseases

Quell Therapeutics, a leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions […]

LaNova Medicines Announces Global Exclusive License Agreement with AstraZeneca for LM-305, a Novel GPRC5D-Targeting Antibody Drug Conjugate

LaNova Medicines has announced it has entered into an exclusive license agreement with AstraZeneca, for […]

Eplontersen Halted ATTRv-PN Disease Progression and Improved Neuropathy Impairment and Quality of Life in Study

Ionis Pharmaceuticals today announced that the Phase 3 NEURO-TTRansform study for AstraZeneca and Ionis’ eplontersen […]

Personalis Selected for Clinical Research by AstraZeneca After Successful Evaluation of Whole Genome-Based Molecular Residual Disease Assay

Personalis, a leader in advanced genomics for precision oncology, today announced it will continue its […]

Vaxzevria Approved in the EU as Third Dose Booster Against COVID-19

AstraZeneca’s COVID-19 vaccine, Vaxzevria (ChAdOx1-S [Recombinant]), has been granted approval in the European Union (EU) by the […]

AstraZeneca Signs Licence Agreement With RQ Biotechnology for Monoclonal Antibodies Against COVID-19

AstraZeneca has entered into a licence agreement with RQ Biotechnology Ltd (RQ Bio) for a […]

BenevolentAI Achieves Third Milestone in Its AI-enabled Drug Discovery Collaboration With AstraZeneca

BenevolentAI (Euronext Amsterdam: BAI), a leading clinical-stage AI-enabled drug discovery company, today announces that AstraZeneca […]

RQ Bio Launches with Goal to Transform Treatment and Prevention of Viral Infectious Diseases Through Antibody Technologies

RQ Bio today emerges from stealth mode announcing its launch as a new UK-based biotechnology […]

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more